Wyeth Files Prevnar 13 Vaccine With FDA; GSK Is Step Ahead With Synflorix In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth is seeking a priority review for its 13-valent pneumococcal vaccine in the U.S., while GSK’s 10-valent version is approved in Europe.
You may also be interested in...
Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position
By picking up serotype 19A, Pfizer's next-generation pneumococcal disease vaccine Prevnar 13 is armed to protect against the most prevalent strain of Streptococcus pneumoniae left in the U.S
Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position
By picking up serotype 19A, Pfizer's next-generation pneumococcal disease vaccine Prevnar 13 is armed to protect against the most prevalent strain of Streptococcus pneumoniae left in the U.S
Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review
An endorsement from FDA's Vaccines and Related Biological Products Advisory Committee for Wyeth's (now Pfizer's) Prevnar 13 would be a positive step for the firm in its race against GlaxoSmithKline rival vaccine Synflorix to capture the next-generation pneumococcal vaccine market